Proteasome inhibitors: all 957 studies that test it

Page 4 of 10. Open to participants first (61), then studies with results posted, then the rest; newest registration first within each.

• Effect of Low Dose Bortezomib on Bone Formation in Smoldering Myeloma PatientsTerminatedNCT00983346Phase 2Results posted
• Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent LymphomaCompletedNCT00980395Phase 2Results posted
• Effect of Combination of Bortezomib/Dexamethasone/Zoledronic Acid on Bone Disease in Patients With Multiple Myeloma Relapsed After 1-3 Prior Lines of TherapyCompletedNCT00972959Phase 2Results posted
• Combination Chemotherapy With or Without Bortezomib in Treating Patients With Classical Hodgkin Lymphoma That Has Returned or Does Not Respond to Prior Treatment.CompletedNCT00967369Phase 2Results posted
• Study Evaluating the Safety and Tolerability of Weekly Dosing of Oral IXAZOMIB in Adult Patients With Relapsed and Refractory Multiple MyelomaCompletedNCT00963820Phase 1Results posted
• Study of Bortezomib in Combination With Cyclophosphamide and RituximabCompletedNCT00958256Phase 2Results posted
• Vorinostat and Bortezomib in Treating Patients With Advanced Soft Tissue SarcomaCompletedNCT00937495Phase 2Results posted
• Study of Oral Ixazomib in Adult Participants With Relapsed and/or Refractory (RR) Multiple MyelomaCompletedNCT00932698Phase 1Results posted
• Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma PatientsCompletedNCT00931918Phase 2Results posted
• A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC)TerminatedNCT00923247Phase 1/2Results posted
• Study of Bendamustine Combined With Bortezomib for Patients With Relapsed/Refractory Multiple MyelomaCompletedNCT00920855Phase 1/2Results posted
• A Clinical Study to Assess the Safety and Activity of SRT501 Alone or in Combination With Bortezomib in Patients With Multiple MyelomaTerminatedNCT00920556Phase 2Results posted
• Desensitization in Kidney TransplantationCompletedNCT00908583Phase 4Results posted
• Treatment With Velcade (Bortezomib) Plus Dexamethasone (VD) or VD Plus Cyclophosphamide or VD Plus Lenalidomide in Patients With Multiple Myeloma Stabilized After 4 Cycles of VDCompletedNCT00908232Phase 2Results posted
• Combination Plerixafor (AMD3100)and Bortezomib in Relapsed or Relapsed/Refractory Multiple MyelomaCompletedNCT00903968Phase 1/2Results posted
• A Study of IXAZOMIB in Adult Patients With LymphomaCompletedNCT00893464Phase 1Results posted
• A Study of Extended Carfilzomib Therapy for Patients Previously Enrolled in Carfilzomib Treatment ProtocolsCompletedNCT00884312Phase 2Results posted
• Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic LymphomaCompletedNCT00873093Phase 2Results posted
• Bortezomib and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative DisordersTerminatedNCT00869323Phase 2Results posted
• Bortezomib and Gemcitabine in Treating Patients With Relapsed B-Cell Non-Hodgkin LymphomaCompletedNCT00863369Phase 1/2Results posted
• Phase I Study of MK-0683 in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-098)CompletedNCT00858234Phase 1Results posted
• Bortezomib, Doxorubicin Hydrochloride Liposome, and Rituximab in Treating Patients With Diffuse Large B-Cell Lymphoma That Has Relapsed or Not Responded to TreatmentTerminatedNCT00851552Phase 2Results posted
• Phase 2 Study of VELCADE With Fludarabine in Comparison to Rituximab With Fludarabine in Follicular Lymphoma Patients Previously Treated With RituximabTerminatedNCT00850499Phase 2Results posted
• Pegylated Liposomal Doxorubicin Hydrochloride, Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Multiple MyelomaTerminatedNCT00849251Phase 1/2Results posted
• Bortezomib and Vorinostat in Treating Patients With Multiple Myeloma Who Have Undergone Autologous Stem Cell TransplantCompletedNCT00839956Phase 2Results posted
• A Study of Bortezomib, Cyclophosphamide, and Dexamethasone in Patients With Untreated Multiple Myeloma and Planned for a High Dose ChemotherapyCompletedNCT00833560Phase 2Results posted
• A Phase 1 Study of IXAZOMIB in Adult Patients With Advanced Nonhematologic MalignanciesCompletedNCT00830869Phase 1Results posted
• Bortezomib and Vorinostat in Treating Patients With High-Risk Myelodysplastic Syndrome or Acute Myeloid LeukemiaTerminatedNCT00818649Phase 2Results posted
• Bortezomib Plus Prednisone for Initial Therapy of Chronic Graft Versus Host DiseaseCompletedNCT00815919Phase 2Results posted
• Study of Bortezomib and Dexamethasone With or Without Cyclophosphamide in Patients With Relapsed or Not Controllable Multiple MyelomaCompletedNCT00813150Phase 3Results posted
• Combination of Vorinostat and Bortezomib in Relapsed or Refractory T-Cell Non-Hodgkin's LymphomaTerminatedNCT00810576Phase 2Results posted
• Vorinostat and Bortezomib as Third-line Treatment in Advanced Non-small Cell Lung CancerCompletedNCT00798720Phase 2Results posted
• Combination High Dose Melphalan and Autologous Peripheral Blood Stem Cell (PBSC) Transplant With Bortezomib for Multiple Myeloma: A Dose and Schedule Finding StudyTerminatedNCT00793650Phase 1/2Results posted
• Autologous or Syngeneic Stem Cell Transplant Followed by Donor Stem Cell Transplant and Bortezomib in Treating Patients With Newly Diagnosed High-Risk, Relapsed, or Refractory Multiple MyelomaCompletedNCT00793572Phase 2Results posted
• Bortezomib, Thalidomide, and Dexamethasone After Melphalan and Stem Cell Transplant in Treating Patients With Stage I-III Multiple MyelomaCompletedNCT00792142Phase 2Results posted
• Melphalan, Bortezomib, and Stem Cell Transplant in Treating Patients With Primary Systemic AmyloidosisCompletedNCT00790647Phase 2Results posted
• Low Dose Melphalan and Bortezomib for AML and High-Risk MDSCompletedNCT00789256Not applicableResults posted
• Study Combining Bortezomib With High Dose Melphalan to Treat Multiple MyelomaCompletedNCT00784823Phase 1/2Results posted
• Study of Vorinostat (MK0683), an Histone Deacetylase (HDAC) Inhibitor in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (MK-0683-095)CompletedNCT00773838Phase 2Results posted
• Rituximab, Cyclophosphamide, Bortezomib, and Prednisone in Patients With Stage III/IV FL or MZLTerminatedNCT00772668Not applicableResults posted
• Randomized Trial for Mixed Acute RejectionCompletedNCT00771875Phase 2Results posted
• Trial of Romidepsin and Bortezomib for Multiple MyelomaTerminatedNCT00765102Phase 2Results posted
• Cyclophosphamide, VELCADE, DOXIL, and Dexamethasone, (CVDD) in Newly Diagnosed Patients With Multiple Myeloma (MM)CompletedNCT00750815Phase 1/2Results posted
• Bortezomib, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid LeukemiaCompletedNCT00742625Phase 1/2Results posted
• Bortezomib With Melphalan and Prednisone for Multiple MyelomaCompletedNCT00734149Phase 2Results posted
• Combination Study of Revlimid®, Velcade® Dexamethasone and Doxil® (RVDD)for Newly Diagnosed Multiple MyelomaCompletedNCT00724568Phase 1/2Results posted
• The Impact of Velcade(TM)on Antibody Secreting Cells in Sensitized Renal Allograft CandidatesCompletedNCT00722722Phase 2Results posted
• Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell LymphomaCompletedNCT00722137Phase 3Results posted
• Study of the Safety and Pharmacokinetics of Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma and Varying Degrees of Renal FunctionCompletedNCT00721734Phase 2Results posted
• An Efficacy and Safety Study of Bortezomib in Participants Previously Treated for Multiple Myeloma With Limited Kidney FunctionTerminatedNCT00718640Phase 2Results posted
• Phase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular LymphomaCompletedNCT00715208Phase 2Results posted
• Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle Cell LymphomaCompletedNCT00711828Phase 2Results posted
• Bortezomib and Vorinostat in Treating Patients With Recurrent Mantle Cell Lymphoma or Recurrent and/or Refractory Diffuse Large B-Cell LymphomaCompletedNCT00703664Phase 2Results posted
• Preemptive Strike With Bortezomib in Multiple Myeloma PatientsTerminatedNCT00657553Phase 3Results posted
• Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple MyelomaActive, not recruitingNCT00644228Phase 3Results posted
• Vorinostat and Bortezomib in Treating Patients With Progressive, Recurrent Glioblastoma MultiformeCompletedNCT00641706Phase 2Results posted
• A Phase I/II Trial of VR-CHOP in Lymphoma PatientsCompletedNCT00634179Phase 1/2Results posted
• Rituximab, Lenalidomide, and Bortezomib in Mantle Cell LymphomaCompletedNCT00633594Phase 1/2Results posted
• Phase II Avastin + Bortezomib for Patients With Recurrent Malignant GliomaCompletedNCT00611325Phase 2Results posted
• Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple MyelomaCompletedNCT00609167Phase 2Results posted
• An Open-Label Study to Assess the Effect of CYP3A4 Induction on the Pharmacokinetics of VELCADE (Bortezomib)CompletedNCT00608907Phase 1Results posted
• Phase 1b Multicenter Study of Carfilzomib With Lenalidomide and Dexamethasone in Relapsed Multiple MyelomaCompletedNCT00603447Phase 1Results posted
• Phase II Trial of Doxorubicin and Bortezomib in Patients With Incurable Adenoid Cystic Carcinoma of the Head and NeckCompletedNCT00581360Phase 2Results posted
• Phase II Trial of Bortezomib and Doxorubicin in Metastatic Breast CancerTerminatedNCT00574236Phase 2Results posted
• UARK 2006-15: A Study of Tandem Transplants With or Without Bortezomib and ThalidomideTerminatedNCT00574080Phase 3Results posted
• VELCADE®-BEAM and Autologous Hematopoietic Stem Cell Transplantation for Non-Hodgkin's Lymphoma, or Mantle Cell LymphomaCompletedNCT00571493Phase 1/2Results posted
• UARK 2005-05, Coagulation-Related Effects of Velcade Treatment in Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT00569868Not applicableResults posted
• Safety Study of Dasatinib With Bortezomib (Velcade®) and Dexamethasone for Multiple MyelomaTerminatedNCT00560352Phase 1Results posted
• Bortezomib and Lenalidomide in Treating Patients With Relapsed or Refractory Mantle Cell LymphomaCompletedNCT00553644Phase 2Results posted
• Sorafenib and Bortezomib Treatment for Relapsed or Refractory Multiple Myeloma PatientsCompletedNCT00536575Phase 1/2Results posted
• Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or LymphomaCompletedNCT00531284Phase 1/2Results posted
• Phase 2 Study of Carfilzomib in Relapsed Multiple MyelomaCompletedNCT00530816Phase 2Results posted
• Bortezomib, Doxorubicin Hydrochloride Liposome, and Thalidomide as First-line Therapy in Treating Patients With Previously Untreated Stage I, II, or III Multiple MyelomaCompletedNCT00523848Phase 2Results posted
• Bortezomib, Melphalan, and Dexamethasone in Treating Patients With Primary Amyloidosis or Light Chain Deposition DiseaseCompletedNCT00520767Phase 2Results posted
• Phase 2 Study of Carfilzomib in Relapsed and Refractory Multiple MyelomaCompletedNCT00511238Phase 2Results posted
• Bortezomib (Velcade) With Standard Chemotherapy for Relapsed or Refractory Follicular LymphomaTerminatedNCT00510887Phase 2Results posted
• Phase II Study of "VIPER" Chemotherapy in Rel/Ref DLBCLCompletedNCT00504751Phase 2Results posted
• Bortezomib and Rituximab for Patients With Waldenstrom's MacroglobulinemiaActive, not recruitingNCT00492050Phase 2Results posted
• A Phase II Trial of Combined Weekly Bortezomib and Tositumomab I-131 in Patients With Relapsed or Refractory Follicular Non-Hodgkin's LymphomaTerminatedNCT00479167Phase 2Results posted
• Bortezomib, Rituximab and Combination Chemotherapy in Treating Participants With Mantle Cell LymphomaCompletedNCT00477412Phase 1/2Results posted
• Velcade, Trisenox, Vitamin C and Melphalan for Myeloma PatientsCompletedNCT00469209Phase 1/2Results posted
• A Phase II Study of Bevacizumab and Bortezomib in Patients With Relapsed/Refractory Multiple MyelomaTerminatedNCT00464178Phase 2Results posted
• Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple MyelomaCompletedNCT00461045Phase 2Results posted
• Melphalan and Autologous Stem Cell Transplant Followed By Bortezomib and Dexamethasone in Treating Patients With Previously Untreated Systemic AmyloidosisCompletedNCT00458822Phase 2Results posted
• Bortezomib, Doxorubicin Hydrochloride Liposome, and Dexamethasone Followed by Thalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Multiple MyelomaCompletedNCT00458705Phase 2Results posted
• Velcade (Bortezomib), Adriamycin Dexamethasone (PAD) or Vincristine Adriamycin Dexamethasone in Second Line Treatment of Multiple MyelomaTerminatedNCT00441168Phase 2Results posted
• Bortezomib With Chemotherapy for Relapsed Pediatric Acute Lymphoblastic Leukemia (ALL)CompletedNCT00440726Phase 1/2Results posted
• Bortezomib and Chemotherapy in Treating Participants With Lymphoid Malignancies Undergoing Stem Cell TransplantCompletedNCT00439556Phase 2Results posted
• Bortezomib and Docetaxel in Treating Patients With Recurrent or Metastatic Head and Neck CancerCompletedNCT00425750Phase 2Results posted
• PS-341 Followed by Removal of Prostate for Those With Prostate CancerCompletedNCT00425503Phase 2Results posted
• Phase I/II Study to Evaluate the Efficacy and Safety of a Combination ChemotherapyTerminatedNCT00424840Phase 1Results posted
• Combination Bortezomib and Rituximab in Patients With Waldenstrom's Macroglobulinemia (WM)CompletedNCT00422799Phase 2Results posted
• Bortezomib and Carboplatin in Treating Patients With Metastatic Pancreatic CancerTerminatedNCT00416793Phase 2Results posted
• VELCADE,Rituximab,Cyclophosphamide and DecadronTerminatedNCT00413959Phase 2Results posted
• Study of VELCADE® With Mitoxantrone and Etoposide for LeukemiasCompletedNCT00410423Phase 1/2Results posted
• Study on the Safety and Effectiveness of VELCADE® in the Treatment of Graft-Versus-Host DiseaseCompletedNCT00408928Phase 2Results posted
• Bortezomib and Pemetrexed Disodium in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid TumorsCompletedNCT00389805Phase 1/2Results posted
• Bortezomib, Ifosfamide, and Vinorelbine Tartrate in Treating Young Patients With Hodgkin's Lymphoma That is Recurrent or Did Not Respond to Previous TherapyCompletedNCT00381940Phase 2Results posted
• Bortezomib Plus CHOP Every 2 Weeks for Advanced Stage DLBCLCompletedNCT00379574Phase 1/2Results posted
• Bortezomib, Lenalidomide, and Dexamethasone Combination Therapy for Patients With Relapsed or Relapsed and Refractory Multiple MyelomaCompletedNCT00378209Phase 2Results posted

← Proteasome inhibitors overview